Navigation Links
Elevation Pharmaceuticals Strengthens Management Team with Appointment of Executives
Date:9/26/2011

SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, today announced the appointment of Jaisim Shah as Senior Vice President and Chief Business Officer and Pravin Soni, PhD, as Senior Vice President and Chief Technical Officer, both newly created positions. The company also announced that it drew down $17 million from its tranched Series A financing, triggered by positive Phase 2a clinical trial results of its lead product, EP-101, for the treatment of chronic obstructive pulmonary disease. The second part of the financing will help fund an ongoing Phase 2b clinical trial of EP-101 for which data is expected by the end of the first quarter 2012.

"Mr. Shah and Dr. Soni bring strong commercial and technical leadership skills to Elevation," stated Bill Gerhart, President and CEO of Elevation.  "Their addition to the Elevation leadership team significantly enhances our ability to develop and optimally position in the marketplace new inhaled drug therapies that meet significant unmet clinical needs."

Mr. Shah is a senior-level commercial and business development executive with 27 years of experience in business development, commercial operations, investor relations, marketing and medical affairs, including leadership positions at F. Hoffman-LaRoche, Bristol-Myers Squibb and PDL BioPharma.  At Elevation, Mr. Shah will be responsible for all product positioning and business development activities.  Prior to Elevation he was President of Zelos Therapeutics, where he focused on financing and business development. Prior to Zelos, he was the Senior Vice President and Chief Business Officer at CytRx, a biopharmaceutical company.  Prior to CytRx, Mr. Shah was Chief Business Officer at Facet Biotech and PDL BioPharma where he completed numerous licensing/partnering and strategic transactions with pharmac
'/>"/>

SOURCE Elevation Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Volcano Corporation Commends the Elevation of FFR to Level of Evidence A in New PCI Guidelines
2. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
3. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
4. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
5. Clermont Pharmaceuticals Reports Positive Phase III Results for Drug to Treat Glaucoma
6. Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
7. Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
8. Zacks Industry Outlook Highlights: Vertex Pharma, AstraZeneca, Abbott Labs, Allergan and Onyx Pharmaceuticals
9. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
10. Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
11. Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... 15 Theranostics Health (TH) today,announced that ... Registration from the,Federal Government. This, along with ... Maryland Department of Health & Mental Hygiene, ... testing in the,disciplines/specialties of Immunology/protein microarray and,Pathology/histopathology., ...
... With Deep Vein, Thrombosis; $10 Million National ... Drug- Device Technique Can Prevent Post-Thrombotic Syndrome, FAIRFAX, ... trial of a catheter-based treatment for deep vein thrombosis,-- ... with clot,removal devices to prevent post-thrombotic syndrome in patients ...
Cached Medicine Technology:Theranostics Health Receives Green Light to Perform Clinical Testing 2Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs 2Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs 3Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs 4
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... January 22, 2015 Lower-Auto-Insurance.com has released a new ... in a car for reducing the costs of an auto ... also be able to get lower prices for their vehicle insurance ... important role in determining policy costs. Because of this, drivers ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... in brain cells may hold clues for Parkinson,s treatment, researchers ... they,ve discovered collections of brain cells that may play a ... in things like playing the piano and driving a car. ... found the cells in the prefrontal cortex and striatum parts ...
... heart patients when ARB added to ACE inhibitor therapy, study ... angiotensin receptor blocker (ARB) drug to help control blood pressure ... are taking an ACE inhibitor, a new study finds. , ... therapy seems no better than ACE inhibitor therapy alone and ...
... Neurologists at the University at Buffalo are beginning ... on the cause of multiple sclerosis (MS). The researchers ... result from narrowing of the primary veins outside the ... CCSVI. CCSVI is a complex vascular condition ...
... Sexual trauma also associated with women,s urinary tract symptoms, ... -- Psychiatric disorders and sexual trauma in women increase ... as incontinence and overactive bladder, a new study finds. ... -- the Urogenital Distress Inventory-6 and Incontinence Impact Questionnaire-7 ...
... antidepressants for depression never get relief. Why? Because ... to treat it aim at the wrong target, according to ... The medications are like arrows shot at the outer rings ... A study from the laboratory of long-time depression researcher Eva ...
... researchers find , FRIDAY, Oct. 23 (HealthDay News) -- A ... seven-day course in reducing pain after children have their tonsils ... in the October issue of the Archives of Otolaryngology ... tonsillectomy can make children reluctant to eat and drink, leading ...
Cached Medicine News:Health News:Adding Drug Doesn't Help Control Blood Pressure 2Health News:Buffalo neurologists investigate possible new underlying cause of MS 2Health News:Buffalo neurologists investigate possible new underlying cause of MS 3Health News:Buffalo neurologists investigate possible new underlying cause of MS 4Health News:Bladder Problems May Often Be Related to Mental Health 2Health News:Why antidepressants don't work for so many 2Health News:Why antidepressants don't work for so many 3Health News:After Tonsillectomy, Short-Term Antibiotics Effective: Study 2
... WristOx® 3100 is a small, ... be worn comfortably on the ... daily activities and for overnight ... the WristOx is intended to ...
... The PulseOx 5500TM is the ... blood oxygen saturation and heart rate ... The PulseOx 5500TM uses SPO Medicals ... device which is more usable for ...
All-in-One Fingertip Oximeter...
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Medicine Products: